AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

Artificial intelligence (AI) is transforming the world at a breakneck speed, with no sector insulated from its potency.

Baron Funds, an investment management company, released its “Baron Asset Fund” first quarter 2025 investor letter. A copy of ...

AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases.

The company focuses on specialty drugs and uses a combination of AI and human expertise to automate the process.

AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, ...

AstraZeneca has returned to recent licensing partner CSPC Pharmaceuticals with $110 million in upfront cash to start work on ...

Rakovina's platform has already attracted interest from multiple pharmaceutical companies seeking differentiated assets and ...

CAMBRIDGE, Mass. and LIVERPOOL, United Kingdom, June 13, 2025 /PRNewswire/ -- XtalPi, a leading life sciences and new ...

Liverpool ChiroChem (LCC), a company founded at the University of Liverpool, has been acquired by XtalPi, a leading life ...

Liverpool ChiroChem (LCC), a company founded at the University of Liverpool, has been acquired by XtalPi, a leading life ...